Evolocumab Reduced CV Events in Diabetes
Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering
-
By
-
Kathryn Wighton
-
April 1, 2026
-
Clinical Scorecard: Evolocumab Reduced CV Events in Diabetes
At a Glance
| Category | Detail |
|---|
| Condition | Diabetes without known significant atherosclerosis |
| Key Mechanisms | Proprotein convertase subtilisin/kexin type 9 inhibition |
| Target Population | Patients with diabetes and elevated lipid levels despite optimized lipid-lowering therapy |
| Care Setting | Outpatient, randomized clinical trial |
Key Highlights
- Evolocumab reduced major cardiovascular events by 2% (absolute risk reduction) compared to placebo.
Guideline-Based Recommendations
Diagnosis
Management
- Initiate evolocumab in high-risk diabetes patients with elevated LDL-C (target <70 mg/dL) despite statin therapy.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
High-risk patients with diabetes and no known significant atherosclerosis.
Evolocumab significantly lowers LDL-C and reduces cardiovascular events.
Clinical Best Practices
- Aim for lower LDL-C targets (<70 mg/dL) in high-risk primary prevention based on evidence from recent studies.
References
